Ticagrelor-induced dyspnoea

Background Ticagrelor, a reversible P2Y12 receptor antagonist, is superior to clopidogrel in decreasing major adverse cardiac events in the setting of acute coronary syndrome. However, a high rate of drug discontinuation secondary to ticagrelor-induced dyspnoea has been observed. Clinical details This is a case of persistent and intolerable ticagrelor-induced dyspnoea in a patient requiring drug discontinuation. A review of the literature on the plausible mechanisms is also provided. Conclusion Dyspnoea is a relatively common side effect of ticagrelor, usually mild and not associated with alteration in pulmonary function. However, in cases of persistent and intolerable dyspnoea, drug discontinuation should be considered. It is imperative that healthcare professionals regularly monitor patients receiving ticagrelor therapy with the aims of maintaining medication adherence and providing appropriate alternatives if dyspnoea becomes intolerable.